You are here

KEYTRUDA® Gets Priority Review for Recurrent or Metastatic Head and Neck Cancers

65,000+ New Diagnoses in U.S. Expected in 2019

The FDA has granted a priority review designation for pembrolizumab injection, 100 mg (Keytruda, Merck) as monotherapy or in combination with chemotherapy for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

KEYNOTE-048, a randomized, open-label phase 3 trial, evaluated pembrolizumab monotherapy or pembrolizumab combination as first-line treatment in 882 patients with recurrent or metastatic HSNCC. The dual primary endpoints were overall survival and progression-free survival.

Head and neck cancer includes various tumors that develop in or around the throat, larynx, nose, sinuses, and mouth. Major risk factors include tobacco and heavy alcohol use, as well as infection with certain types of human papillomaviruses. It is estimated that there will be more than 65,000 new cases of head and neck cancer diagnosed this year in the U.S.

Pembrolizumab is an anti-PD-1 therapy that increases the immune system’s ability to help detect and fight tumor cells. It is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

The FDA has set a target action date of June 10, 2019 for pembrolizumab.

Source: Merck, February 11, 2019

Recent Headlines

Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen
Zip Device Faster to Apply, Minimizes Scarring